Logo image of PRTK

PARATEK PHARMACEUTICALS INC (PRTK) Stock Fundamental Analysis

NASDAQ:PRTK - Nasdaq - US6993743029 - Common Stock - Currency: USD

2.23  +0.04 (+1.83%)

After market: 2.23 0 (0%)

Fundamental Rating

2

Overall PRTK gets a fundamental rating of 2 out of 10. We evaluated PRTK against 193 industry peers in the Pharmaceuticals industry. PRTK may be in some trouble as it scores bad on both profitability and health. PRTK shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRTK had negative earnings in the past year.
PRTK had a negative operating cash flow in the past year.
PRTK had negative earnings in each of the past 5 years.
PRTK had a negative operating cash flow in each of the past 5 years.
PRTK Yearly Net Income VS EBIT VS OCF VS FCFPRTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

PRTK has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRTK Yearly ROA, ROE, ROICPRTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200 -200 300

1.3 Margins

The Gross Margin of PRTK (85.71%) is better than 89.57% of its industry peers.
In the last couple of years the Gross Margin of PRTK has grown nicely.
The Profit Margin and Operating Margin are not available for PRTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5YN/A
PRTK Yearly Profit, Operating, Gross MarginsPRTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100K -200K -300K

More info and screens

0

2. Health

2.1 Basic Checks

PRTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRTK has been increased compared to 1 year ago.
The debt/assets ratio for PRTK is higher compared to a year ago.
PRTK Yearly Shares OutstandingPRTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
PRTK Yearly Total Debt VS Total AssetsPRTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

PRTK has an Altman-Z score of -9.64. This is a bad value and indicates that PRTK is not financially healthy and even has some risk of bankruptcy.
PRTK has a Altman-Z score of -9.64. This is in the lower half of the industry: PRTK underperforms 75.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.64
ROIC/WACCN/A
WACC7.65%
PRTK Yearly LT Debt VS Equity VS FCFPRTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

PRTK has a Current Ratio of 0.52. This is a bad value and indicates that PRTK is not financially healthy enough and could expect problems in meeting its short term obligations.
PRTK has a worse Current ratio (0.52) than 92.42% of its industry peers.
PRTK has a Quick Ratio of 0.52. This is a bad value and indicates that PRTK is not financially healthy enough and could expect problems in meeting its short term obligations.
PRTK's Quick ratio of 0.46 is on the low side compared to the rest of the industry. PRTK is outperformed by 92.42% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.46
PRTK Yearly Current Assets VS Current LiabilitesPRTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.67% over the past year.
Looking at the last year, PRTK shows a very strong growth in Revenue. The Revenue has grown by 59.83%.
Measured over the past years, PRTK shows a very strong growth in Revenue. The Revenue has been growing by 66.25% on average per year.
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y66.25%
Sales Q2Q%34.94%

3.2 Future

PRTK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.93% yearly.
The Revenue is expected to grow by 22.58% on average over the next years. This is a very strong growth
EPS Next Y32.14%
EPS Next 2Y41.42%
EPS Next 3Y26.53%
EPS Next 5Y31.93%
Revenue Next Year9.93%
Revenue Next 2Y25.23%
Revenue Next 3Y14.33%
Revenue Next 5Y22.58%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PRTK Yearly Revenue VS EstimatesPRTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PRTK Yearly EPS VS EstimatesPRTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTK Price Earnings VS Forward Price EarningsPRTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTK Per share dataPRTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PRTK's earnings are expected to grow with 26.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y26.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PARATEK PHARMACEUTICALS INC

NASDAQ:PRTK (9/20/2023, 8:00:00 PM)

After market: 2.23 0 (0%)

2.23

+0.04 (+1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-03 2023-08-03/bmo
Earnings (Next)11-01 2023-11-01/bmo
Inst Owners0.15%
Inst Owner Change361.84%
Ins Owners6.47%
Ins Owner Change0%
Market Cap127.82M
Analysts80
Price Target3.16 (41.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.04%
Min EPS beat(2)18.3%
Max EPS beat(2)21.78%
EPS beat(4)2
Avg EPS beat(4)-53.61%
Min EPS beat(4)-226.05%
Max EPS beat(4)21.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.81%
Min Revenue beat(2)1.8%
Max Revenue beat(2)15.83%
Revenue beat(4)3
Avg Revenue beat(4)5.25%
Min Revenue beat(4)-13.37%
Max Revenue beat(4)16.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-41.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.96%
EPS NY rev (1m)14.05%
EPS NY rev (3m)22.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.68%
Revenue NY rev (1m)3.71%
Revenue NY rev (3m)5.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.09
BVpS-3.51
TBVpS-3.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.71%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5YN/A
F-Score5
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.39%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.46
Altman-Z -9.64
F-Score5
WACC7.65%
ROIC/WACCN/A
Cap/Depr(3y)56.09%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.37%
Cap/Sales(5y)0.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
EPS Next Y32.14%
EPS Next 2Y41.42%
EPS Next 3Y26.53%
EPS Next 5Y31.93%
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y66.25%
Sales Q2Q%34.94%
Revenue Next Year9.93%
Revenue Next 2Y25.23%
Revenue Next 3Y14.33%
Revenue Next 5Y22.58%
EBIT growth 1Y34.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.4%
OCF growth 3YN/A
OCF growth 5YN/A